Elevated expression of ALKBH5 in liver cancer patients is strongly associated with the upregulation of immune-suppressive markers, such as PD-L1, which facilitate immune escape and contribute to tumor progression by impeding effective immune surveillance. Here, ALKBH5 is linked to liver cancer.